post asco/eha 2023 roundtable discussion- targeting bruton tyrosine kinase in cll in 2023 and beyond
Published 1 year ago • 342 plays • Length 1:11:42Download video MP4
Download video MP3
Similar videos
-
1:27:28
the iach post asco/eha 2022 roundtable discussion: a focus on multiple myeloma
-
52:52
post comy-asco-eha round table - antibody-drug conjugates in rrmm
-
46:14
cll: key take-home messages from eha and asco 2024
-
1:21:01
nhl-cll post ash 2023 round table debate by the iach
-
51:26
updates in cll - 2023 best of hematology conference
-
33:30
bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: context and impact of new data
-
1:15:31
mpn post ash 2023 round table debate by the iach
-
8:55
bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia (cll) with tp53 mutations
-
1:01:22
chronic lymphocytic leukemia at ash21: what's new?
-
7:12
cardiovascular events in patients with chronic lymphocytic leukemia (cll) - asco 2022
-
12:40
treatment options for cll after bruton’s tyrosine kinase inhibitor and venetoclax (bcl2i) - ash 2021
-
7:26
pirtobrutinib and prior bcl2 inhibitor exposure in cll - ash 2023 dr. jennifer woyach
-
6:34
chronic lymphocytic leukemia (cll) treatment options for elderly patients - asco 2023
-
10:08
pirtobrutinib for chronic lymphocytic leukemia (cll) after btk inhibitor - dr. jennifer woyach
-
9:54
outcomes and sequences of target therapies in cll (chronic lymphocytic leukemia) - ash 2023
-
21:32
precision medicine in chronic lymphocytic leukemia (cll)
-
12:09
acalabrutinib vs. ibrutinib for treatment of chronic lymphocytic leukemia (cll) - dr. lindsey roeker
-
11:27
treatments for chronic lymphocytic leukemia (cll) after btk inhibitor - dr. meghan thompson ash 2022